Search

Your search keyword '"Gainor, J."' showing total 29 results

Search Constraints

Start Over You searched for: Author "Gainor, J." Remove constraint Author: "Gainor, J." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
29 results on '"Gainor, J."'

Search Results

5. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy

6. 1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)

7. Monstrous Regiment (1975-1993)

8. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

10. 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)

11. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

12. MA15.09 LCMC3: Long-Term Disease-Free and Overall Survival and their Association with ctDNA after Neoadjuvant Atezolizumab for NSCLC

17. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

18. Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors

22. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis.

23. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.

24. TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state.

25. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

26. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.

27. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.

28. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.

29. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 + advanced non-small cell lung cancer.

Catalog

Books, media, physical & digital resources